English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 8 November 2018, 08:43 HKT/SGT
Share:
    

Source: Eisai
Eisai Commences Full-Scale Operation of New Suzhou Plant in China
Strengthens In-House Domestic Production System in China

TOKYO, Nov 8, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has commenced full-scale operation of its new Suzhou plant located within the Suzhou Industrial Park, and an opening ceremony was held accordingly.

http://www.acnnewswire.com/topimg/Low_EisaiNewSuzhou%20.jpg
(from left: Kazuyuki Katayama, Consulate-General of Japan in Shanghai; Wu Qingwen, Deputy Mayor, Suzhou Municipality, SIPAC Secretary General of the Party Committee; Haruo Naito, Eisai Co., Ltd. CEO; Wang Yue, Jiangsu Food and Drug Administration Head of Bureau)

Aiming to further expand its contribution to patients in China, Eisai has been working to establish the new Suzhou plant as the plant with the largest production capacity under the Eisai Group on a new industrial site more than five times larger than the former Suzhou plant (oral solid dose production facility scheduled for closure at the end of November 2018) at approximately 134,000m2 in size to further strengthen the stable supply chain as well as improve production efficiency. The new Suzhou plant's oral solid dose production facility has a production capacity (formulation of approximately 3 billion tablets / packaging for approximately 5 billion tablets per year) which is approximately double that of the former Suzhou plant, and handles the formulation and packaging of oral solid dose products such as Methycobal, Aricept and Pariet for the domestic Chinese market. In addition, ECI established a parenteral facility (production capacity: 60 million bottles per year) in advance in November 2014, where it manufactures the injection formulation of Methycobal.

Eisai's business operations in China are one of its core businesses which is third-largest in scale after Japan and the United States. With the full-scale commencement of operations at the new Suzhou plant, Eisai seeks to strengthen its in-house domestic production system in China and expand its stable supply chain of high quality pharmaceuticals, contributing to increasing the benefits to patients and their families in China.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 
Multimedia
(from left: Kazuyuki Katayama, Consulate-General of Japan in Shanghai; Wu Qingwen, Deputy Mayor, Suzhou Municipality, SIPAC Secretary General of the Party Committee; Haruo Naito, Eisai Co., Ltd. CEO; Wang Yue, Jiangsu Food and Drug Administration Head of Bureau)
View Image
 

Eisai Releated News
Nov 12, 2018 12:00 HKT/SGT
エーザイ、中国において「レンビマ」(レンバチニブ)を新発売
Nov 12, 2018 11:51 HKT/SGT
Eisai Launches Lenvima (Lenvatinib) in China
Nov 9, 2018 09:00 HKT/SGT
エーザイとMSD、「レンビマ」(レンバチニブ)と「キイトルーダ」(ペムブロリズマブ)との併用療法について3がん腫に対する最新の研究成果を第33回がん免疫学会年次総会にて発表
Nov 9, 2018 08:08 HKT/SGT
Eisai: New Data from Investigational Study of Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
Nov 8, 2018 14:38 HKT/SGT
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Anti-Fractalkine Antibody E6011 for Treatment of Crohn's Disease Concluded, Research Activities Commence
More news >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: